Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season

Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid.